Objective To evaluate the efficacy and safety of aspirin monotherapy and aspirin combining with clopidogrel therapy in treating transient ischemic attack (TIA) according to different risk stratification. Methods A total of 122 TIA patients was divided into 2 groups: single resistance group (treated only by aspirin) and dual anti-platelet aggregation group (treated with aspirin and clopidogrel). According to Age, Blood pressure, Clinical features, Duration, and Diabetes plus Dual TIA (ABCD3-Ⅰ) score, they were further divided into low-risk, middle-risk and high-risk groups. The incidences of ischemic stroke and adverse events in each group were evaluated. Results After 3-week treatment, the incidence of ischemic stroke in low-risk groups was both 0, while it was 9/20 in middle-risk single resistance group, 2/19 in middle-risk dual anti-platelet aggregation group, 10/19 in high-risk single resistance group, and 3/20 in high-risk dual anti-platelet aggregation group. The differences among those groups were statistically significant (P = 0.031, 0.019). The most common drug adverse reactions were nausea and acid regurgitation ( χ2 = 0.000, P = 1.000). No obvious bleeding tendency or liver and kidney dysfunction was found. Conclusions ABCD3-Ⅰ score may be used as the safety evaluation index of anti-platelet drugs. The application of aspirin combining with clopidogrel may have an advantage over aspirin monotherapy in the prevention of ischemic stroke.?DOI: 10.3969/j.issn.1672-6731.2015.01.011.
展开▼
